Oral medication slows rheumatoid arthritis joint damage

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month interim analysis of the efficacy of tofacitinib appear in Arthritis amp; Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).
Virtual Medical Centre - Pain News

Share:

Related Content